TrialNeuro-oncology2009

Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).

Patrick Y Wen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.